Intelligence · Clinical Pipeline
Eli Lilly and Pipeline
All ClinicalTrials.gov programs at Eli Lilly and — phase, modality, and trial IDs.
- Programs
- 8
Quick answer
Eli Lilly and has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Donanemab
Eli Lilly and Company
Cognitive Dysfunction
1 trial -
Eltrekibart
Eli Lilly and Company
Ulcerative Colitis
1 trial -
LY2157299
Eli Lilly and Company
Carcinoma, Hepatocellular
1 trial -
LY3454738
Eli Lilly and Company
Atopic Dermatitis
1 trial -
LY4268989
Eli Lilly and Company
Ulcerative Colitis (UC)
1 trial -
Mirikizumab - Intravenous (IV)
Eli Lilly and Company
Colitis, Ulcerative
1 trial -
Ramucirumab
Eli Lilly and Company
Gastric Adenocarcinoma
1 trial -
Selpercatinib
Eli Lilly and Company
Medullary Thyroid Cancer
1 trial
Frequently asked questions
How many pipeline programs does Eli Lilly and have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs